Loading stock…

Incyte Corporation (INCY) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Incyte Corporation

INCYMarket cap $23BPrice $112.7

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops targeted therapies for cancer and inflammatory diseases, built on a blockbuster JAK inhibitor that dominates myelofibrosis treatment. One drug, Jakafi, still drives the majority of its revenue nearly a decade after launch.

In Bastion Portfolios?

52W Return+29%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+15%8

Revenue Forecast

Rev CAGR (1y)+15%7

Rev CAGR (3y)+9%6

Rev CAGR (5y)-0%1

Earnings Forecast

EPS Growth Y+1-47%2

EPS Growth Y+2+166%10

EPS Growth Y+3+5%5

Quality

Margins

EBIT Margin32%9

Net Income Margin28%9

Free Cash Flow Margin33%9

Debt

Net Debt/EBITDA-2.310

Efficiency

ROE31%9

ROA24%10

Earnings Stability44

GEAR+VERY STRONG86

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)511

P/E Ratio (Forward 3y)126

P/BV3.64

EV Multiples

EV/EBITDA Fwd242

EV/EBIT Fwd214

Yield

Free Cash Flow Yield8.4%8

Dividend Yieldna–

Momentum

Short term

1 month return-11%2

3 month return-5%5

YTD return+14%7

Mid term

Price vs 52wHigh85%6

1 year return+29%8

Long term

3 year return+97%7

5 year return+72%7

Risk Shield

Price Risk

Beta0.39

Volatility33%6

Free Cash Flow

Free Cash Flow Margin33%9

Free Cash Flow Yield8.4%8

Quality

ROCE33%10

Earnings Stability44

Net Debt/EBITDA-2.310

02Growth

Is it actually growing, and how fast?

INCYIncyte

Revenue FY25$5.1B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+15%8

Revenue, next 1Y+15%7

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR-0%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-47%2

EPS growth, FY27E+166%10

EPS growth, FY28E+5%5

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 15%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, in line with the market.5/10

Revenue grew 15%/yr over the last 3 years; forecasts see it cooling to 9%/yr.

Earnings are set to grow in step with sales (EPS about 5%/yr vs revenue 9%/yr). One year dips: EPS falls 47% next year.

WEAKNESSES

Over five years revenue is set to hold flat, behind 90% of companies worldwide.1/10

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE53 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return-5%5

YTD return+14%7

MID & LONG-TERM▾SCORE

% of 52-week high85%6

1-year return+29%8

3-year return+97%7

5-year return+72%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +97% over three years and +72% over five, ahead of 60% of the market.

It's up 29% over the past year, but 15% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+14%).

WATCH

Returns sit at the market level over three months (-5%).

WEAKNESSES

The stock is underperforming over the past month (-11%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over the past month.

04Value

Are you paying a fair price for it?

Stop guessing on Incyte. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

INCYIncyte

Revenue FY25$5.1B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+15%8

Revenue, next 1Y+15%7

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR-0%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-47%2

EPS growth, FY27E+166%10

EPS growth, FY28E+5%5

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 15%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, in line with the market.5/10

Revenue grew 15%/yr over the last 3 years; forecasts see it cooling to 9%/yr.

Earnings are set to grow in step with sales (EPS about 5%/yr vs revenue 9%/yr). One year dips: EPS falls 47% next year.

WEAKNESSES

Over five years revenue is set to hold flat, behind 90% of companies worldwide.1/10

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE53 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return-5%5

YTD return+14%7

MID & LONG-TERM▾SCORE

% of 52-week high85%6

1-year return+29%8

3-year return+97%7

5-year return+72%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +97% over three years and +72% over five, ahead of 60% of the market.

It's up 29% over the past year, but 15% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+14%).

WATCH

Returns sit at the market level over three months (-5%).

WEAKNESSES

The stock is underperforming over the past month (-11%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over the past month.

04Value

Are you paying a fair price for it?

Stop guessing on Incyte. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community